Jay McGill

Jay McGill, PhD

Chief Operating Officer

Jay McGill

Jay McGill, PhD

Chief Operating Officer

Jay McGill, PhD is Indiana Bioscience Research Institute's Chief Operating Officer (COO). Dr. McGill brings a strong background of industrial experience, operations, and working in innovation across the industrial-academic boundaries. Most recently, Dr. McGill served as senior Director at Eli Lilly and Company in Lilly Research Laboratories responsible for science and technology partnerships. In this role, Dr. McGill served as the interface between academic institutions and Lilly Research Labs as well as overseeing Lilly's portfolio of research-based public/private partnerships and consortium participation.

In 2012-2014, Dr. McGill was on assignment as a loaned executive with BioCrossroads where he held the title of Translational Scientific Officer. His responsibilities at BioCrossroads included the support of several initiatives at the Indiana Clinical and Translational Institute (Indiana CTSI) at the Indiana University School of Medicine. He also provided support in the creation of the Indiana Biosciences Research Institute. Dr. McGill also was instrumental in establishing the Indiana CTSI–Covance partnership for a Phase 1 Clinic within IU Hospital and played a critical role in creating the Strategic Pharma-Academic Research Consortium for Translational Medicine (SPARC). Dr. McGill served as the Chief Operations Officer and Treasurer for the Fairbanks Institute for Healthy Communities.

Previous to his assignment at BioCrossroads, Dr. McGill was the Senior Director of Research Business Operations where his responsibilities included oversight and management of all research-based (preclinical) collaborations, alliances, and outsourcing partners, including chemistry, in vitro and in vivo biology, preclinical ADME and toxicology. Dr. McGill also was responsible for the research quality and compliance organizations. From December 2010 to June 2012, he served as Interim COO of the Lilly China Research Development Center (LCRDC) in Shanghai, China. After Eli Lilly announced its intentions to create a research and development site in China, Dr. McGill led a team to identify a location, construct the facility and establish the operations for LCRDC, which opened in June 2012.

After receiving a Bachelor of Science degree in chemistry from the University of Georgia and a PhD in organic chemistry from Indiana University, Dr. McGill joined Eli Lilly and Company in 1990 as a Senior Scientist in the Chemical Process Development Group. In 1998, he joined the Discovery Chemistry Research and Technologies organization and held a number of positions including Head of the Custom Synthesis Lab, Director of the Discovery Chemistry Synthesis Group, Sr. Director – Global Chemistry Sourcing. In 2008, as part of reorganization within Lilly Research Laboratories, all of the research-based sourcing groups (chemistry, in vitro and in vivo biology, toxicology and ADME) were consolidated under Dr. McGill’s leadership as Senior Director, External Research Operations.

Dr. McGill has more than 25 years of experience in pharmaceutical research and development, research collaborations, and outsourcing management. He has been instrumental in creating and developing Eli Lilly’s collaborations in Asia and establishing operations to support an external network of research-based outsourcing partners and alliances. Dr. McGill is known for his leadership in the pioneering of novel and transformational partnership models.